The conference will present preliminary findings of the Bridge AI project, an ambitious initiative coordinated by INESC-ID, in collaboration with the Champalimaud Foundation and Unbabel. Leading academics, entrepreneurs, policymakers, and interested citizens will gather to discuss the implications and implementation of the European Union’s AI Act.

With fully functional inpatient and recovery units, as well as operating rooms, the Centre is now prepared to significantly expand the Champalimaud Foundation's capacity to treat pancreatic cancer patients. With a dedicated team of specialists in the treatment and research of this type of cancer, the Centre's mission is to deliver the highest standard of clinical care.

Natural ageing is one of the main risk factors for cancer. As we become older, the probability of developing cancer increases. This happens, on the one hand, because the probability of acquiring cancer-causing mutations grows as we live longer; and on the other, because our DNA repair mechanisms decline with age.

This congress reaffirmed the collaboration between the two countries in the research and treatment of neurodegenerative diseases such as Alzheimer's, a condition with a higher incidence in aging societies like those of Spain and Portugal, and with a profound economic and social impact.

Here are some recurrent unproven claims:

Co-organised by Fundación CIEN, Fundación Reina Sofía, and the Champalimaud Foundation, this scientific congress aims to bring advances in research in the fight against Alzheimer's and other neurodegenerative diseases to the public, and above all, to raise awareness to advance the search for global solutions and responses due to their social consequences.

Experts from two international nuclear medicine societies (EANM and SNMMI) have joined those from important societies of various other medical specialities involved in the care of breast cancer patients – including oncology, surgery, radio-oncology and breast imaging – to draw up a set of recommendations, based on scientific evidence, on the correct utilisation, in breast cancer, of a medical imaging exam. The exam in question has been used for several years and involves radioactive substances, in this case a glucose analogue called fluorodeoxyglucose (FDG).

Claes Dohlman, emeritus professor of Ophthalmology and former chair of the Department of Ophthalmology at Mass Eye and Ear and Harvard Medical School, died on July 14, 2024. He was 101.

Often recognized as the “father” of modern corneal science, Dohlman shared the 2022 António Champalimaud Vision Award with Gerrit Melles, from the Netherlands Institute for Innovative Ocular Surgery in Rotterdam.

Host

Adriana Sánchez Danés, Principal Investigator, Champalimaud Research

Venue

Seminar room

Abstract

To overcome the complexities of cancer and pave a path towards a cure, the McManus Lab is developing innovative approaches that consider both the genetic drivers of the disease and its interactions within the cellular environment. Join Dr. McManus to explore new technologies and methods to combat this multifaceted complex human disease.

The images created during the daily scientific and medical endeavours at the Champalimaud Foundation can be as beautiful and compelling as any work of art. To the untrained eye, these images might also appear baffling, but, if you know what you’re looking at, they may just reveal information that can spark discoveries, contribute to the improvement of patient quality of life and maybe even alter our understanding of reality.